-
Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF635 at KeyBanc as 'Strong Fundamentals Continue'
-
Lonza Group AG (LONN:SW) (LZAGY) PT Raised to CHF680 at Berenberg
-
Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF660 at CFRA
-
KeyBanc Reiterates Overweight Rating on Lonza Group AG (LONN:SW) (LZAGY), Citing Highest 2025 Growth
-
Berenberg Reiterates Buy Rating on Lonza Group (LONN:SW) (LZAGY)
-
KeyBanc Reiterates Overweight on Lonza Group AG (LONN:SW) (LZAGY); 'Investor Day Includes Positive Reads for LONN'
-
Lonza Group AG (LONN:SW) (LZAGY) PT Raised to CHF723 at CLSA
-
Elevation Oncology (ELEV) Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
-
Goldman Sachs Starts Lonza Group AG (LONN:SW) (LZAGY) at Buy
-
Lonza Group AG (LONN:SW) (LZAGY) PT Raised to CHF590 at RBC Capital
-
Jefferies Reiterates Buy Rating on Lonza Group AG (LONN:SW) (LZAGY)
-
Lonza Group AG (LONN:SW) (LZAGY) PT Raised to CHF666 at Bernstein SocGen Group

